Wellington Management Group LLP Has $449,000 Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Wellington Management Group LLP raised its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 10.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,067 shares of the company’s stock after buying an additional 10,821 shares during the quarter. Wellington Management Group LLP owned about 0.18% of Larimar Therapeutics worth $449,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of LRMR. Barclays PLC increased its holdings in Larimar Therapeutics by 321.2% in the 3rd quarter. Barclays PLC now owns 60,032 shares of the company’s stock worth $393,000 after purchasing an additional 45,781 shares in the last quarter. SG Americas Securities LLC increased its stake in Larimar Therapeutics by 35.1% during the 4th quarter. SG Americas Securities LLC now owns 19,391 shares of the company’s stock valued at $75,000 after purchasing an additional 5,042 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Larimar Therapeutics in the 3rd quarter worth about $100,000. Franklin Resources Inc. raised its stake in shares of Larimar Therapeutics by 21.9% in the third quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock worth $143,000 after purchasing an additional 3,549 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in Larimar Therapeutics by 80.1% during the 3rd quarter. Jane Street Group LLC now owns 113,783 shares of the company’s stock valued at $745,000 after acquiring an additional 50,622 shares in the last quarter. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Trading Up 3.3 %

Shares of NASDAQ:LRMR opened at $1.87 on Tuesday. Larimar Therapeutics, Inc. has a 12-month low of $1.61 and a 12-month high of $11.20. The stock’s 50-day moving average price is $2.63 and its 200-day moving average price is $4.66. The stock has a market capitalization of $119.73 million, a P/E ratio of -1.63 and a beta of 0.91.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.16). As a group, research analysts predict that Larimar Therapeutics, Inc. will post -1.15 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Robert W. Baird cut their target price on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. HC Wainwright boosted their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, March 25th. Truist Financial initiated coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price objective on the stock. Citigroup restated a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Finally, Guggenheim restated a “buy” rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Larimar Therapeutics presently has an average rating of “Buy” and an average target price of $19.63.

Larimar Therapeutics Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.